Skip to content

Trusted Messenger Intervention

Preliminary Study of a Trusted Messenger Intervention to Promote Vaccine Uptake in Adult Inpatient Psychiatric Hospitals

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05167422
Enrollment
2
Registered
2021-12-22
Start date
2021-09-14
Completion date
2023-07-14
Last updated
2023-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaccine Hesitancy

Brief summary

The objective of this pilot study is to develop and evaluate test a trusted messenger intervention targeting vaccine hesitancy in patients on an inpatient psychiatric hospital setting with both acute and chronic patients.

Interventions

BEHAVIORALTrusted Messenger

A nested waitlist design in which patients and staff are nested within two inpatient psychiatric units. New Hampshire Hospital staff will be trained to deliver the trusted messenger intervention up to 24 patients on the first unit while the second unit receives care as usual, during which time in-house vaccinations among patients on both units will be tracked in a registry. After a 3-week study period, up to 24 patients on the second unit will receive the trusted messenger intervention and followed for a period of 3 weeks. The trusted messenger intervention will consist of staff who are trained to engage patients informally and assist building social norms for vaccine uptake supported by weekly and as-needed check-ins with a content expert who can answer specific vaccine related questions over a 3 week period.

Sponsors

Dartmouth-Hitchcock Medical Center
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Intervention model description

Nested quasi-experimental

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Able and willing to give verbal informed consent to participate in the study or able to assent with guardian consent * Expected to remain in the hospital for the duration of the study * Mental health diagnosis Demographics * Male, female, or transgender (no

Exclusion criteria

based on gender or sexual orientation) * Ages 18 or older * Any race or ethnicity * English speaking

Design outcomes

Primary

MeasureTime frameDescription
Vaccine acceptance- This will be measured using the COVID Vaccine Hesitancy QuestionnaireParticipant is willing to receive the vaccine by the end of week 6 of participation from baseline.The participant is willing to receive the COVID-19 vaccine

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026